Please describe your clinical practice; how many patients do you currently treat with CKD, what percent of your patients are on dialysis and what are the treatment options? How often do patients develop hyperphosphatemia?

Can you tell us in more detail about the difficulties faced when controlling serum phosphorus in adult patients with chronic kidney disease?

What are the pros and cons of phosphate binders? Have the traditional issues of large pill size, objectionable taste, and multiple pills required for each meal and snack make phosphate been resolved ? What would you like to see in this space as an improvement?

How often do gastrointestinal AEs lead to treatment discontinuation?

What percent of dialysis patients have phosphorus concentrations of <5.5 mg/dl, to normal levels of <4.5 mg/dl? How much of a need is there?

Can you talk to us about your experience with tenapanor, which targets the dominant paracellular pathway, what advantages could xpozah have vs standard of care?

What percent of your patients had to stop treatment due to nontolerance, adverse effects?

How likely are you to prescribe XPHOZAH to your CKD Dialysis patients given its recent approval?

Do you view greater utility for XPHOZAH in lowering pill burden in combination with phosphate binders or more as a monotherapy for those who are intolerant?